Search results for "lipodystrophy"

showing 10 items of 18 documents

Impaired DNA demethylation of C/EBP sites causes premature aging

2018

Changes in DNA methylation are among the best-documented epigenetic alterations accompanying organismal aging. However, whether and how altered DNA methylation is causally involved in aging have remained elusive. GADD45α (growth arrest and DNA damage protein 45A) and ING1 (inhibitor of growth family member 1) are adapter proteins for site-specific demethylation by TET (ten-eleven translocation) methylcytosine dioxygenases. Here we show that Gadd45a/Ing1 double-knockout mice display segmental progeria and phenocopy impaired energy homeostasis and lipodystrophy characteristic of Cebp (CCAAT/enhancer-binding protein) mutants. Correspondingly, GADD45α occupies C/EBPβ/δ-dependent superenhancers …

0301 basic medicinePremature agingAgingLipodystrophyDNA damageCell Cycle ProteinsBiology03 medical and health sciencesMiceGeneticsAnimalsHomeostasisEpigeneticsCells CulturedDemethylationMice KnockoutNuclear ProteinsAging PrematureMethylationCell biologyChromatinDNA Demethylation030104 developmental biologyDNA demethylationDNA methylationCCAAT-Enhancer-Binding ProteinsInhibitor of Growth Protein 1Developmental BiologyResearch Paper
researchProduct

Kosaki overgrowth syndrome: A novel pathogenic variant in PDGFRB and expansion of the phenotype including cerebrovascular complications

2020

Heterozygous activating variants in platelet-derived growth factor, beta (PDGFRB) are associated with phenotypes including Kosaki overgrowth syndrome (KOGS), Penttinen syndrome and infantile myofibromatosis (IM). Here, we present three new cases of KOGS, including a patient with a novel de novo variant c.1477A > T p.(Ser493Cys), and the oldest known individual age 53 years. The KOGS phenotype includes characteristic facial features, tall stature, scoliosis, hyperelastic thin skin, lipodystrophy, variable intellectual and neurological deterioration, and abnormalities on brain imaging. Long-term outcome is unknown. Our cases confirm the phenotypic spectrum includes progressive flexion contrac…

AdultMale0301 basic medicinePathologymedicine.medical_specialtyInfantile myofibromatosisPDGFRBScoliosis030105 genetics & heredityCraniosynostosisReceptor Platelet-Derived Growth Factor beta03 medical and health sciencesCamptodactylyGeneticsmedicineHumansJoint dislocationStrokeGrowth DisordersGenetics (clinical)business.industryGenetic VariationMiddle Agedmedicine.diseaseCerebrovascular DisordersPhenotype030104 developmental biologymedicine.symptomLipodystrophybusinessClinical Genetics
researchProduct

Age-Related Lipid Metabolic Signature in HumanLMNA-Lipodystrophic Stem Cell-Derived Adipocytes

2015

Lamin A (LMNA)-linked lipodystrophies belong to a group of clinical disorders characterized by a redistribution of adipose tissue with a variable range of metabolic complications. The leading cause of these disorders is the nonphysiological accumulation of the lamin A precursor, prelamin A. However, the molecular mechanisms by which prelamin A induces the pathology remain unclear.The aim of this study is to use an experimental LMNA-lipodystrophy model based on human mesenchymal stem cell (hMSC)-derived adipocytes that accumulate prelamin A to gain deeper insights into the mechanisms governing these diseases.Prelamin A-induced or -noninduced hMSC-derived adipocytes were obtained from healthy…

AdultMaleAgingcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentLipodystrophyLipolysisEndocrinology Diabetes and MetabolismCellular differentiationClinical BiochemistryAdipose tissueMitochondrionBiologyBiochemistryLMNAYoung AdultEndocrinologyInternal medicineAdipocytesmedicineHumansMetabolomicsLipolysisintegumentary systemStem CellsBiochemistry (medical)Mesenchymal stem cellnutritional and metabolic diseasesCell DifferentiationMiddle AgedLamin Type ALipid MetabolismEndocrinologyMetabolomeFemaleStem cellLaminThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Relapsing and Progressive Complications of Severe Hypertriglyceridemia: Effective Long-Term Treatment with Double Filtration Plasmapheresis

2019

<b><i>Background:</i></b> Severe hypertriglyceridemia (HTG) is associated with major complications such as acute or relapsing pancreatitis (AP) and atherosclerotic cardiovascular disease (ASCVD). Rapid elimination of triglyceride (TG)-rich lipoproteins (LP) with double filtration plasmapheresis (DFPP) without need for substitution has been found to be effective for the acute, short-term treatment of HTG-induced AP. Data on the long-term use of DFPP to prevent HTG-associated complications are scarce. <b><i>Objectives:</i></b> To evaluate the use and efficacy of regular DFPP treatment in clinical practice for preventing recurrence of HTG-associa…

AdultMalemedicine.medical_specialtyMedizin030232 urology & nephrology030204 cardiovascular system & hematologySeverity of Illness IndexGastroenterology03 medical and health sciences0302 clinical medicinePharmacotherapyRefractoryRecurrenceInterquartile rangeInternal medicinemedicineHumansRetrospective StudiesHypertriglyceridemiaPregnancybusiness.industryHypertriglyceridemiaPlasmapheresisHematologyGeneral MedicineMiddle Agedmedicine.disease3. Good healthTreatment OutcomeNephrologyDisease ProgressionAcute pancreatitisFemaleLipodystrophybusinessComplicationBlood Purification
researchProduct

Adverse drug reactions to antiretroviral medication

2009

Antiretroviral therapy has greatly improved prognosis of HIV infection, with a dramatic reduction of morbidity and mortality worldwide. Nevertheless, the condition is still a common cause of death in many underdeveloped countries, where effective treatment is not always unavailable. More than 20 drugs active against HIV are commercially available, which belong to one of four groups: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and fusion/entry inhibitors. In the near future new drugs are expected, including those of a novel group, the integrase inhibitors. To avoid viral resistance, combinations of the drugs must always b…

LipodystrophyAnti-HIV Agentsmedicine.medical_treatmentIntegrase inhibitorHIV InfectionsBioinformaticsCardiovascular SystemNervous SystemNucleoside Reverse Transcriptase InhibitorDrug HypersensitivityBone MarrowHumansMedicineEffective treatmentLactic AcidDrug reactionUrinary TractAdverse effectProteasebusiness.industryOsteonecrosisReverse transcriptaseGastrointestinal TractBone Diseases MetabolicLiverPancreatitisAntiretroviral medicationbusinessFrontiers in Bioscience
researchProduct

Different origin of adipogenic stem cells influences the response to antiretroviral drugs

2015

Lipodystrophy (LD) is a main side effect of antiretroviral therapy for HIV infection, and can be provoked by nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs). LD exists in different forms, characterized by fat loss, accumulation, or both, but its pathogenesis is still unclear. In particular, few data exist concerning the effects of antiretroviral drugs on adipocyte differentiation. Adipose tissue can arise either from mesenchymal stem cells (MSCs), that include bone marrow-derived MSCs (hBM-MSCs), or from ectodermal stem cells, that include dental pulp stem cells (hDPSCs). To analyze whether the embryonal origin of adipocytes might impact the occurrence of d…

LipodystrophyPharmacologyBiologyAntiviral Agentschemistry.chemical_compoundFatty acid bindingDental pulp stem cellsLipid dropletAdipocytemedicineAdipocytesReverse transcriptaseAnimalsHumansDental PulpInhibitorsStavudineMesenchymal stem cellMesenchymal Stem CellsCell BiologyProtease inhibitorsVirologyRetroviridaechemistryAdipogenesisAntiretroviral drugsStem cellAntiretroviral drugs; Inhibitors; Lipodystrophy; Protease inhibitors; Reverse transcriptasemedicine.drugRetroviridae Infections
researchProduct

Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV- and HCV- infected patients

2013

BACKGROUND: Conflicting data have been reported on the prevalence of liver steatosis, its risk factors and its relationship with fibrosis in patients with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection or with HCV mono-infection. AIM: The study aims were to assess steatosis prevalence and its risk factors in both HCV groups. We also evaluated whether steatosis was linked with advanced fibrosis. Sixty-eight HIV/HCV co-infected and 69 HCV mono-infected patients were consecutively enrolled. They underwent liver ultrasonography and transient elastography. Bright liver echo-pattern was used to diagnose steatosis; advanced fibrosis was defined as liver stiffness ≥ 9.5 kPa…

Liver CirrhosisMaleHepatic steatosisTransient elastographySpecialties of internal medicineHIV Infectionsmedicine.disease_causeGastroenterologyRisk FactorsFibrosisPrevalenceFIB–4CoinfectionGeneral MedicineHepatitis CMiddle AgedItalyRC581-951Area Under CurveFIB-4Elasticity Imaging TechniquesFemaleLipodystrophyAdultmedicine.medical_specialtyHepatitis C virusLiver fibrosisHepatic steatosiWhite PeopleHIV/HCV co-infectionPredictive Value of TestsInternal medicinemedicineHumansChi-Square DistributionHepatologybusiness.industryLiver fibrosiHepatitis C Chronicmedicine.diseaseImpaired fasting glucoseFatty LiverLogistic ModelsROC CurveMultivariate AnalysisSteatosisMetabolic syndromeTransient elastographybusinessBiomarkersAnnals of Hepatology
researchProduct

Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection

2012

Background: Limited data are available on hepatic steatosis (HS) in HIV patients who are not infected with hepatitis C virus (HCV). The aims of this study were to assess the prevalence of HS and its risk factors in HIV patients with and without HCV infection, and to evaluate whether HS correlates with advanced liver fibrosis and/or cardiovascular disease risk. Methods: Fifty-seven HIV mono-infected and 61 HIV/HCV co-infected patients were enrolled consecutively. All patients underwent liver ultrasound and transient elastography. The main parameters of liver function, HIV and HCV viral loads, CD4+ cell counts, and data on highly active antiretroviral therapy (HAART) were recorded. Cardiovasc…

Liver CirrhosisMaleSteatosisSettore MED/09 - Medicina InternaLipodystrophyAntiretroviral medicationHIV Infectionsmedicine.disease_causeGastroenterologyHIV/HCV co-infectedLiver diseaseRisk FactorsAntiretroviral Therapy Highly ActivePrevalenceMedicineProspective StudiesSteatosis HIV HIV/HCV co-infected Non-alcoholic fatty liver disease Liver disease Antiretroviral medication Metabolic syndrome LipodystrophyUltrasonographyeducation.field_of_studySettore MED/12 - GastroenterologiaFramingham Risk ScoreCoinfectionvirus diseasesGeneral MedicineMiddle AgedMetabolic syndromeHepatitis CInfectious DiseasesCardiovascular DiseasesFemaleLipodystrophyLiver diseaseViral loadMicrobiology (medical)Adultmedicine.medical_specialtySettore MED/17 - Malattie InfettiveAnti-HIV AgentsHepatitis C virusPopulationInternal medicineHumanseducationbusiness.industryHIVmedicine.diseaseFatty LiverImmunologyMultivariate AnalysisLiver functionbusinessTransient elastographyNon-alcoholic fatty liver disease
researchProduct

De Novo Mutations in SLC25A24 Cause a Disorder Characterized by Early Aging, Bone Dysplasia, Characteristic Face, and Early Demise

2017

International audience; A series of simplex cases have been reported under various diagnoses sharing early aging, especially evident in congenitally decreased subcutaneous fat tissue and sparse hair, bone dysplasia of the skull and fingers, a distinctive facial gestalt, and prenatal and postnatal growth retardation. For historical reasons, we suggest naming the entity Fontaine syndrome. Exome sequencing of four unrelated affected individuals showed that all carried the de novo missense variant c.649C>T (p.Arg217Cys) or c.650G>A (p.Arg217His) in SLC25A24, a solute carrier 25 family member coding for calcium-binding mitochondrial carrier protein (SCaMC-1, also known as SLC25A24). SLC25A24 all…

Male0301 basic medicineAgingMitochondrionPetty syndromeAntiportersATP-Mg/Pi carriersAdenosine TriphosphateCytosol0302 clinical medicineAdenine nucleotideMissense mutation[ SDV.GEN.GH ] Life Sciences [q-bio]/Genetics/Human geneticsGenetics (clinical)Exome sequencingMembrane Potential MitochondrialGeneticsProgeriaATP synthaseSCaMC-1SyndromeMitochondria3. Good healthFemalemedicine.medical_specialtylipodystrophyMolecular Dynamics SimulationBiologyPhosphatesMitochondrial Proteins03 medical and health sciencesReportInternal medicineGeneticsmedicineHumansFetal DeathBone Diseases DevelopmentalAdenineSLC25A24Calcium-Binding ProteinsagingInfant NewbornInfantprogeriaFibroblastsmedicine.diseaseMitochondrial carrierSolute carrier familyOxygenprogeroid disorder030104 developmental biologyEndocrinology[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsMutationbiology.protein030217 neurology & neurosurgery
researchProduct

Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence

2011

The combined antiretroviral therapeutic approach currently employed for the treatment of HIV infection, known as Higly Active Antiretroviral Therapy (HAART), has dramatically reduced AIDS-related morbidity and mortality. However, the adverse reactions associated with the long term use of this therapy have now become a major issue and researchers have focused on understanding the cellular mechanisms underlying these drug-induced detrimental effects which englobe a large list of different events including rash and hypersensibility reactions, hepatotoxicity, metabolic disturbances including lipodystrophy, and other metabolic syndrome-like disturbances such as hyperlactatemia, hyperlipedimia, i…

PharmacologyMitochondrial DNAAnti-HIV AgentsMitochondrionBiologyPharmacologymedicine.diseaseDNA MitochondrialReverse transcriptaseMitochondriaMitochondrial toxicityInsulin resistancePharmacotherapyAntiretroviral Therapy Highly ActiveDrug DiscoverymedicineHumansDrug Therapy CombinationHyperlactatemiaLipodystrophyCurrent Pharmaceutical Design
researchProduct